Key result
High rates of preventive aspirin use (up to 26% in lung cancer patients) create a frequent clinical dilemma regarding perioperative continuation during major lung resection.
Why the study?
Is it safe to continue perioperative low-dose aspirin therapy in patients undergoing major lung resection?
Is it safe to continue perioperative low-dose aspirin therapy in patients undergoing major lung resection?
Answers are grounded in this paper and cite their sources.
Highlights the clinical dilemma thoracic surgeons face regarding the continuation or discontinuation of low-dose aspirin during the perioperative period for major lung resection.
Aspirin is widely used for the primary and secondary prevention of cardiovascular disease. Gu et al . estimated the prevalence of preventive aspirin use in the US adult population from the National Health and Nutrition Examination Survey, 2011–2012, and about one-third of the US adults aged more than 40 years used aspirin for preventive purposes (1). Some population-based studies reported that among patients diagnosed with lung cancer, 15.3% in Korea and 26% in Sweden were aspirin users (2,3). Accordingly, thoracic surgeons are frequently confronted with patients taking aspirin and need to decide whether to continue or discontinue aspirin in the perioperative period.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2019) conducted an editorial in Lung cancer undergoing major lung resection. Perioperative low dose aspirin therapy was evaluated. High rates of preventive aspirin use (up to 26% in lung cancer patients) create a frequent clinical dilemma regarding perioperative continuation during major lung resection.
Synapse has enriched 10 related papers. Consider them for comparative context: